Literature DB >> 24217530

[Current treatment of tachycardia].

J Tebbenjohanns1, K Rühmkorf.   

Abstract

Tachycardias including atrial fibrillation often require hospitalisation. A diagnostic algorithm from the surface ECG allows discrimination between supraventricular and ventricular tachycardias. For acute treatment, only a few antiarrhythmic drugs such as adenosine, ajmaline and amiodarone, and in case of hemodynamic instability electrocardioversion are required. For long-term treatment catheter ablation is the option of choice for almost all patients with supraventricular tachycardias, atrial flutter, idiopathic ventricular tachycardias and for many patients with symptomatic atrial fibrillation. Chronic antiarrhythmic drug therapy is less often used. In patients with ventricular tachyarrhythmias in the setting of severe structural heart disease, risk stratification must be performed and ICD therapy is often indicated. Anticoagulant therapy according to risk score analysis is often indicated in patients with atrial fibrillation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24217530     DOI: 10.1007/s00108-013-3325-5

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  10 in total

1.  Anterior-posterior versus anterior-lateral electrode positions for external cardioversion of atrial fibrillation: a randomised trial.

Authors:  Paulus Kirchhof; Lars Eckardt; Peter Loh; Karoline Weber; Rudolf-Josef Fischer; Karl-Heinz Seidl; Dirk Böcker; Günter Breithardt; Wilhelm Haverkamp; Martin Borggrefe
Journal:  Lancet       Date:  2002-10-26       Impact factor: 79.321

2.  2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design.

Authors:  Hugh Calkins; Karl Heinz Kuck; Riccardo Cappato; Josep Brugada; A John Camm; Shih-Ann Chen; Harry J G Crijns; Ralph J Damiano; D Wyn Davies; John DiMarco; James Edgerton; Kenneth Ellenbogen; Michael D Ezekowitz; David E Haines; Michel Haissaguerre; Gerhard Hindricks; Yoshito Iesaka; Warren Jackman; Jose Jalife; Pierre Jais; Jonathan Kalman; David Keane; Young-Hoon Kim; Paulus Kirchhof; George Klein; Hans Kottkamp; Koichiro Kumagai; Bruce D Lindsay; Moussa Mansour; Francis E Marchlinski; Patrick M McCarthy; J Lluis Mont; Fred Morady; Koonlawee Nademanee; Hiroshi Nakagawa; Andrea Natale; Stanley Nattel; Douglas L Packer; Carlo Pappone; Eric Prystowsky; Antonio Raviele; Vivek Reddy; Jeremy N Ruskin; Richard J Shemin; Hsuan-Ming Tsao; David Wilber
Journal:  Europace       Date:  2012-03-01       Impact factor: 5.214

3.  Lenient versus strict rate control in patients with atrial fibrillation.

Authors:  Isabelle C Van Gelder; Hessel F Groenveld; Harry J G M Crijns; Ype S Tuininga; Jan G P Tijssen; A Marco Alings; Hans L Hillege; Johanna A Bergsma-Kadijk; Jan H Cornel; Otto Kamp; Raymond Tukkie; Hans A Bosker; Dirk J Van Veldhuisen; Maarten P Van den Berg
Journal:  N Engl J Med       Date:  2010-03-15       Impact factor: 91.245

4.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.

Authors:  Manesh R Patel; Kenneth W Mahaffey; Jyotsna Garg; Guohua Pan; Daniel E Singer; Werner Hacke; Günter Breithardt; Jonathan L Halperin; Graeme J Hankey; Jonathan P Piccini; Richard C Becker; Christopher C Nessel; John F Paolini; Scott D Berkowitz; Keith A A Fox; Robert M Califf
Journal:  N Engl J Med       Date:  2011-08-10       Impact factor: 91.245

5.  [Guidelines for catheter ablation].

Authors:  Karl-Heinz Kuck; Sabine Ernst; Uwe Dorwarth; Ellen Hoffmann; Heinz Pitschner; Jürgen Tebbenjohanns; Hans Kottkamp
Journal:  Clin Res Cardiol       Date:  2007-11       Impact factor: 5.460

6.  2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association.

Authors:  A John Camm; Gregory Y H Lip; Raffaele De Caterina; Irene Savelieva; Dan Atar; Stefan H Hohnloser; Gerhard Hindricks; Paulus Kirchhof
Journal:  Eur Heart J       Date:  2012-08-24       Impact factor: 29.983

7.  Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study.

Authors:  Leif Friberg; Mårten Rosenqvist; Gregory Y H Lip
Journal:  Eur Heart J       Date:  2012-01-13       Impact factor: 29.983

8.  Apixaban versus warfarin in patients with atrial fibrillation.

Authors:  Christopher B Granger; John H Alexander; John J V McMurray; Renato D Lopes; Elaine M Hylek; Michael Hanna; Hussein R Al-Khalidi; Jack Ansell; Dan Atar; Alvaro Avezum; M Cecilia Bahit; Rafael Diaz; J Donald Easton; Justin A Ezekowitz; Greg Flaker; David Garcia; Margarida Geraldes; Bernard J Gersh; Sergey Golitsyn; Shinya Goto; Antonio G Hermosillo; Stefan H Hohnloser; John Horowitz; Puneet Mohan; Petr Jansky; Basil S Lewis; Jose Luis Lopez-Sendon; Prem Pais; Alexander Parkhomenko; Freek W A Verheugt; Jun Zhu; Lars Wallentin
Journal:  N Engl J Med       Date:  2011-08-27       Impact factor: 91.245

9.  Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins.

Authors:  M Haïssaguerre; P Jaïs; D C Shah; A Takahashi; M Hocini; G Quiniou; S Garrigue; A Le Mouroux; P Le Métayer; J Clémenty
Journal:  N Engl J Med       Date:  1998-09-03       Impact factor: 91.245

10.  Dabigatran versus warfarin in patients with atrial fibrillation.

Authors:  Stuart J Connolly; Michael D Ezekowitz; Salim Yusuf; John Eikelboom; Jonas Oldgren; Amit Parekh; Janice Pogue; Paul A Reilly; Ellison Themeles; Jeanne Varrone; Susan Wang; Marco Alings; Denis Xavier; Jun Zhu; Rafael Diaz; Basil S Lewis; Harald Darius; Hans-Christoph Diener; Campbell D Joyner; Lars Wallentin
Journal:  N Engl J Med       Date:  2009-08-30       Impact factor: 91.245

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.